Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Air Leak From Lung
Interventions
Polyglycolic acid felt, Standard of care
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bleeding
Interventions
TachoSil®, Surgicel® Original
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more
Conditions
Pediatric HD, Bleeding
Interventions
Fibrinogen, Cryoprecipitate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
Up to 24 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 2 Interventional Results available

The Fibrin Patch Soft Tissue Study

NCT00658723
Conditions
Hemostasis
Interventions
Fibrin Pad, SURGICEL™
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
Conditions
Hemostasis
Interventions
Fibrinogen Concentrate (FC), Cryoprecipitate
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Day to 30 Days
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
Interventions
RiaStAP, Saline
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
1 Day to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Miami, Florida
Conditions
Congenital Fibrinogen Deficiency
Interventions
FCH
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Las Vegas, Nevada • Durham, North Carolina
Completed Phase 4 Interventional Results available

Open Label Use Of RiaStap During Aortic Reconstruction

NCT01300286
Conditions
Coagulopathic Bleeding
Interventions
RiaSTAP
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

The Fibrin Pad Cardiovascular Study

NCT01681030
Conditions
Cardiovascular Disease
Interventions
EVARREST™, Topical hemostat, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
Conditions
Excessive Bleeding During Surgery
Interventions
Fibrin Sealant Grifols, EVICEL
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Up to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chicago, Illinois • Michigan Center, Michigan • Albany, New York + 9 more
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Results available

GATT-Patch Versus TachoSil in Liver Surgery

NCT05385952
Conditions
Intraoperative Bleeding, Hemorrhage, Surgical, Liver Diseases
Interventions
GATT-Patch (currently named ETHIZIA), TachoSil
Device · Drug
Lead sponsor
GATT Technologies BV
Industry
Eligibility
22 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Los Angeles, California • St Louis, Missouri • Newark, New Jersey + 3 more
Conditions
Congenital Fibrinogen Deficiency, Afibrinogenemia
Interventions
Octafibrin, Haemocomplettan® P or RiaSTAPTM
Biological
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • New Hyde Park, New York
Conditions
Blood Loss, Surgical
Interventions
Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel)
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more
Completed Phase 3 Interventional Results available

The Fibrin Pad CV Phase III Study

NCT02040428
Conditions
Cardiovascular Disease
Interventions
EVARREST™ Fibrin Sealant Patch, Topical hemostat
Biological
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Completed Phase 2 Interventional Results available

Human Fibrinogen - Pharmacokinetics

NCT00496262
Conditions
Fibrinogen Deficiency
Interventions
Human Fibrinogen Concentrate
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • St. Petersburg, Florida • Chicago, Illinois + 3 more
Conditions
Osteoarthritis
Interventions
Evicel fibrin sealant
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
20 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

EVARREST™ Fibrin Sealant Patch Post-Market Study

NCT01902459
Conditions
Hemorrhage, Soft Tissue Bleeding
Interventions
EVARREST™ Fibrin Sealant Patch, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 3 Interventional Results available

A Study of Fibrocaps™ in Surgical Bleeding

NCT01527357
Conditions
Mild or Moderate Surgical Bleeding
Interventions
Fibrocaps, Gelatin sponge
Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Conditions
Coagulopathy
Interventions
ROTEM, Cryoprecipitate, RiaSTAP
Device · Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

The EVARREST® Fibrin Sealant Patch Liver Study

NCT01993888
Conditions
Hemorrhage
Interventions
EVARREST® Fibrin Sealant Patch, Standard of Care (SoC)
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • Augusta, Georgia • Chicago, Illinois + 5 more